Breaking Research News from sources other than Breastcancer.org
Comments
-
Thank you, LilyIsHere! very glad I could pop in. Schedule has been hectic lately but I am trying to ad a bit here and there. I get notifications of posts and enjoy following the postings/discussion.
0 -
NIH Director Francis Collins On Covid, Faith, And The Future Of Medical Research In The U.S.
Doctor Francis Collins is stepping down as director of the National Institutes of Health after 12 years. He reflects on his legacy and his agency's efforts in the fight against COVID-19.
https://dianerehm.org/audio/#/shows/2021-10-22/nih-director-francis-collins-on-covid-faith-and-the-future-of-medical-research-in-the-u-s/116534
@{@45 minute interview by Diane Rehm. Not exclusively, or even primarily, about cancer research, but may be of interest to those interested in NIH, medical research and some of the humans behind this work. No charge for access. You'll have to copy and paste the *full* web address to get to the right episode.}
0 -
TNBC Vaccine to prevent recurrences: trial
0 -
Lumpie, you were missed! Glad to see you posting again. I love this thread as I learn so much - I keep my MO on his toes…LOL
Santabarbarian, that is an interesting trial. I hope it proves to be a success!
0 -
I join the chorus celebrating Lumpie. I missed her posts. Thank you Lumpie. Glad to see you back and I hope all is well with you.
0 -
Study: Eating nuts improves survival rate in breast cancer
A study in the International Journal of Cancer found that breast cancer survivors who consumed more than one-half ounce of nuts a week had 94% five-year survival and disease-free survival rates, while those who didn't consume nuts regularly only had an 89% five-year survival rate and an 86% disease-free survival rate. The findings also revealed that 94% of the participants who ate nuts regularly did not report return of their breast cancer within half a decade of recovery.
Full Story: United Press Internationalhttps://www.upi.com/Health_News/2021/10/20/breast-cancer-nuts-survival-study/1631634735622/
https://onlinelibrary.wiley.com/doi/10.1002/ijc.33824
{Golly. That's a plus. The study only evaluated 5 years and notes that long term study is needed. Free access to both reporting and to the journal article. (I don't know why it's still underlining....) }
0 -
You are all too kind and generous with the very nice comments! It is good to be missed. Thank you!
0 -
I love nuts but they are expensive and not very filling despite being highly caloric. They're basically dessert for health-concscious fancy people.
My first impulse was that nuts are standing here as a proxy for socio-economic status and it was interesting to me that when they adjusted by income, nuts actually made no impact on overall survival.
0 -
Only a 1/2 oz of nuts a week isn't much. I've been eating 2 tblsp a week for some time & it has helped lower my cholesterol. Of course almonds & pistachios are better for you than cashew nuts. And naturally un-salted are better too. Sometimes they are dessert, but just as often I throw them in a salad.
0 -
I remember hearing that walnuts, specifically, may be good for breast cancer patients. Here’s a mouse study -
https://pubmed.ncbi.nlm.nih.gov/30979659/
And I think there are other studies with walnuts
0 -
I have been eating nuts every day for many years and I keep them at work, car, home even though my kids are allergic to tree nuts. I even mix nuts with honey and eat them as dessert. Since starting letrozole I am finding them difficult to digest and I don't eat as much anymore.
Salamandra, you can find them cheap at Costco.
0 -
Agree about the Costco prices. Yes walnuts are high on all the 'good' lists. Unfortunately I am allergic to walnuts & macadamia nuts - but I eat all the rest.
0 -
Walnuts are good for your brain as well. Here in Ky you can find walnuts for free if you want to go to the trouble to crack them open yourself.
0 -
Ooohh yes good to see you Lumpie and a real pic of Cure-ious!
0 -
I'm wondering, in these instances where funding a human trial is an issue, does Metavivor come in to help fund? I give 2% of my net commissions to a handful of charities and of course Metavivor is one and the next one up for a check.
0 -
I received a response from Bayer about the emails I have been sending with requests for ErSO clinical trials:
Thank you for your inquiry regarding one of our drugs in development, ErSO. As you may have read, it has shown promising results in pre-clinical models of breast cancer. However, before it can be tried in humans, additional safety tests (such as in primates) must be undertaken, and that is where the compound currently is in development. We try to move our compounds through development as quickly as possible, but at the same time we have to take the prudent steps to ensure that the compounds are safe and provide the potential benefits we are striving to achieve (and thus the tests in other species such as primates). Because of these necessary steps the drug is not currently available for trials in humans. However, we hope to be able to provide an update on the status of the program before the end of the year.
If you would like to contact me in a 6-8 weeks, I may be able to give you a more definitive schedule.
You should know that Bayer posts its human clinical trials for all of its drugs on clinicaltrials.gov and that is another source for ongoing (or soon to start) clinical trials.
I hope that your doctors find ways to control your cancer in the meantime.
Sincerely,
Joseph Germino, MD, PhD
Vice President USMA
Bayer Healthcare
0 -
WOW, Kale!! Great job, and thanks so much!
0 -
Go Kale!
0 -
GoKale,
Wow, it's wonderful he responded to you. Thanks for sharing.
0 -
GoKale, thank you so much for taking the initiative on this. Wonderful that you received what appears to be a personalized response. Can you share the email address you used to contact Mr. Germino?
Praying that ErSO reaches human trial phase soon and that it actually works! I'm very cautiously optimistic.
0 -
MoCoGram - here is the email address for Dr. Germino
joseph_f.germino@bayer.com
0 -
Someone asked about METAvivor funding for research. METAvivor has a research funding application process. It takes place once or twice a year. Petitioners must complete a grant application. This is typical in the grant application/research "space." Applicants are scored and ranked by a scientific team and by patient advocates team. Scoring relates to chance of success and potential impact. A board makes final decisions about awards. Those interested in applying can find more info on the METAvivor website.
0 -
Sharing this update from the American Cancer Society's Cancer Action Network:
Exciting news! We have recently released some initial findings of our last Survivor Views survey, which focuses on patient experiences with telehealth and issues around clinical trial participation. As noted by ACS CAN president Lisa Lacasse in today's press release, "These data suggest we have a real opportunity to make clinical trial participation easier for all patients by removing barriers to participation, including through the use of telehealth technologies and reducing out-of-pocket costs."
To all those who responded to our Summer 2021 survey, THANK YOU! You've contributed your voice to our mission of improving the lives of cancer patients and survivors. With the Survivor Views project, we do this by making sure you are heard by the decision makers shaping health policy.
If you haven't yet responded to our current survey, which covers topics like paid medical leave for patients and caregivers, please click the following link to respond by November 15th:
https://survey.us.confirmit.com/wix/p925353504545.aspx
{If you are interested in signing up for the ACS Cancer Action Network, you can do so here:
The group does both advocacy and fundraising. You can pick and choose your level of participation.}
0 -
A very interesting episode (there are more - please check): https://www.ourmbclife.org/episodes/rtac-lin-parso...
Also lot's of useful information and articles.
Saulius
0 -
Thanks for that link Saulius! Great conversation.
0 -
https://investor.lilly.com/news-releases/news-rele...
FDA has approved Verzenio for HR+ HER2 -, node positive high-risk early breast cancer
"This subgroup analysis (N=2,003) included patients with ≥4 positive axillary lymph nodes (ALN), or 1-3 positive ALN with either Grade 3 disease and/or tumor size ≥5 cm, and whose tumors had a Ki-67 score of ≥20%. There was also a statistically significant improvement in IDFS for this pre-specified subgroup of patients receiving Verzenio plus ET compared to those who received ET alone."
"The number of IDFS events at the time of this analysis was 104 with Verzenio plus ET compared to 158 with ET alone."
0 -
Jenny - man that stuff has some bad side affects.
0 -
HomeMom,
Thankfully, I don't meet their definition of "high-risk", so I won't be adding this to my treatment regimen. But if I did, I would be happy to know that this was an additional option to help prevent metastatic recurrence.
0 -
FDA is Moving Away from the Maximum Tolerated Dose!
The decades-long paradigm of leveraging the highest and most toxic dose of a cancer drug, called the Maximum Tolerated Dose (MTD), will be coming to an end.
Shortly after the PCDI's presentation about MBC patients' treatment-related side effects at ASCO's 2021 worldwide conference, Richard Pazdur, Director of the FDA's Oncology Center of Excellence, stated that the FDA will start requiring drug companies to test the efficacy of multiple drug doses during clinical trials instead of identifying and moving forward with the MTD.
This is a game-changer because the MTD, which is identified in Phase 1 clinical trials that focus solely on toxicity, is the dose that generally causes the most severe side effects. In today's world, whenever patients with MBC begin a new treatment, they are generally prescribed the MTD unless there's a medical contraindication. But in tomorrow's world, at least two doses will be identified in Phase 1 clinical trials for further study so that ultimately the optimal dose - based upon a balance of efficacy and toxicity - will be given to patients.
If this subject interests you, please consider joining a webinar hosted by Friends of Cancer Research on Wednesday, Nov. 10th at 12PM ET. Panelists including the FDA, pharmaceutical companies, Friends of Cancer Research, and the PCDI, will be discussing the transformation of MTD-based oncology studies.
You may register here for the free conference!
Thank you,
Anne Loeser, Author,Founder PCDI
{The above is from an email dated 11/6/2021 from Anne Loesser. Some of you may have received it. This is great news IMO. Less toxicity while maintaining efficacy is what we all want. I believe that the Friends of Cancer Research session on Patient Centered Dosing is only one hour long.}
0 -
Hi Lumpie, re MTD can I just jump in and say that I have NEVER tolerated the Max Dose of pretty much any cancer drug. I’ve had a few now and they have always required reductions because the side effects are just awful. So far we’ve managed to get to a reasonable level albeit with plenty of side effects. I agree that we should not be accepting the max dose just because that’s where the clinical trials are pitched. Much more research required!
0
